Cresco assisted Droia Oncology Ventures in its pre-seed investment in Montis, a biotech startup developing an immunotherapy for cancer.
Less than one year after the incorporation, Cresco assisted Droia, Polaris Innovation Fund, Alsa Ventures and Pfizer in making a Seed Series investment in Montis, bringing total amounts raised to €8.4 million.
Montis’ mission is to therapeutically exploit cellular interactions between perivascular macrophages and tumor vasculature to drive and sustain immune reactions against solid tumors.
David Dessers led the Cresco team that advised Droia and the other investors in this transaction.
More information on this transaction can be found in De Tijd.
For any further information or questions, please contact David Dessers.